晚期乳腺癌-βtubulinⅢ和survivin的表达及与多西紫杉醇化疗疗效相关性分析

Analysis of the relationship between expression of β-tubulinⅢ,survivin and response to docetaxel in metastatic breast cancer

目的:探讨晚期乳腺癌中-βtubulinⅢ和survivin的表达与多西紫杉醇化疗疗效的关系。方法:回顾性分析84例接受多西紫杉醇化疗的晚期乳腺癌患者的临床病理资料。免疫组织化学法检测肿瘤标本-βtubulinⅢ和survivin蛋白的表达,并对疗效、不良反应进行分析。结果:-βtubu-linⅢ阳性表达率为38.1%(32/84),survivin阳性表达率为76.2%(64/84)。化疗有效率(CR+PR)为52.38%,-βtubulinⅢ(+)的患者有效率低(37.50%),-βtubulinⅢ(-)患者有效率高(61.54%),差异有统计学意义(P<0.05)。sur-vivin(+)组的有效率为48.40%,低于survivin(-)组的65.00%,差异有统计学意义P<0.05)。联合检测显示:-βtubulinⅢ(+)且sur-vivin(+)组有效率为25.0%,中位疾病无进展期为3.9个月,1年、2年生存率分别为34.5%、15.1%,-βtubulinⅢ(-)且survivin(-)组有效率为73.91%,中位疾病无进展期为7.7个月,1年、2年生存率分别为61.6%、31.4%,差异均有统计学意义(P<0.05)。最常见的不良反应为骨髓抑制、消化道反应和脱发。结论:联合检测-βtubu-linⅢ和survivin的表达可作为多西紫杉醇化疗方案治疗转移性乳腺癌的疗效预测指标之一。

AIM：To investigate the expression of β-tubulinⅢ,survivin protein and chemoresistance to docetaxel in advanced gastric cancer. METHODS： Seventy-four patients of advanced gastric cancer treated with docetaxel were enrolled in this study and their tumor samples were collected retrospectively for analysis.The expression of β-tubulinⅢ,survivin protein in tumor samples was detected by the immuno-histochemical methods.The data of therapeutical effect and toxicity were collected and analyzed.RESULTS：β-tubulinⅢ positive staining accounted for 38.1%（32/84）.Survivin positive staining accounted for 76.2%（64/84）.There was no correlation between β-tubulinⅢ,survivin positive expression and age,gender,pathological type.The response rate（CR＋PR）was 52.38%.Patients with overexpression β-tubulinⅢ were less response rate（37.50%vs 61.54%） to docetaxel（P0.05）.Patients with overexpression survivin were less response rate（48.40%vs 65.50%） to docetaxel（P0.05）.Patients with overexpression β-tubulinⅢ and survivin were also lower response rate（25.0%vs 73.91%,P0.05）.Patients with over expression β-tubulinⅢ and survivin have also lower the median time to progress and 1-and 2-year survival rates（3.9m vs 7.7m,34.5% vs 61.6%,15.1% vs 31.4%,P0.05）.The main side-effects were myelosuppression and digestive apparatus toxicity.CONCLUSION： The expression of β-tubulinⅢ and survivin is associated with clinical response to docetaxel chemotherapy in metastatic breast cancer and can be used as method of detection of sensitivity.